According to Fortune Business Insights, the global women health diagnostics market size was valued at USD 27.07 billion in 2025 and is projected to grow from USD 28.77 billion in 2026 to USD 47.66 billion by 2034, exhibiting a CAGR of 6.5% during the forecast period from 2026 to 2034. North America dominated the market in 2025, accounting for a 34.65% share.
Market Overview
The women health diagnostics market is evolving as healthcare providers and patients increasingly emphasize early detection and preventive care. Routine cervical cancer screening, breast imaging, STI testing, fertility diagnostics, pregnancy testing, and osteoporosis assessments represent important areas of demand.
The increasing incidence of conditions such as cancer, osteoporosis, infertility, and infectious diseases is further supporting the need for diagnostic tests and devices. At the same time, healthcare providers are adopting automated and connected diagnostic technologies to improve testing efficiency and turnaround times.
For detailed market insights: https://www.fortunebusinessinsights.com/women-s-health-diagnostics-market-111885
Market Trends
AI-Enabled Women's Imaging and Workflow Automation
Artificial intelligence (AI) is emerging as a significant trend in women's imaging. Breast diagnostics are increasingly incorporating AI for detection, breast-density assessment, triage, and workflow optimization. Healthcare systems are looking for technologies that can improve diagnostic efficiency and provide more consistent results.
For example, in November 2024, GE HealthCare and RadNet's DeepHealth announced a collaboration to develop SmartTechnology AI solutions for imaging. The initiative began with the integration of DeepHealth's SmartMammo with GE HealthCare's Senographe Pristina mammography system to improve breast cancer screening efficiency and accuracy.
The adoption of AI-enabled imaging can enhance radiologists' efficiency, potentially reduce unnecessary biopsies, and support demand for advanced diagnostic equipment.
Market Drivers
Expansion of Women's Health Test Kits
The expansion of women's health test kits is a major factor driving market growth. More women are undergoing routine cervical cancer screening, breast imaging, and STI testing due to public health initiatives, updated guidelines, and increased payer coverage.
The increasing incidence of cancer, osteoporosis, and infertility is also generating demand for diagnostic test kits and devices, including follow-up diagnostic procedures. For instance, the source notes that approximately 316,950 women in the U.S. were projected to receive a diagnosis of invasive breast cancer in 2025, along with 59,080 cases of non-invasive breast cancer.
However, reimbursement gaps and affordability challenges can limit adoption of advanced diagnostics, particularly in lower-resource settings. Competition for healthcare budgets and limited government initiatives for certain tests can further restrict market penetration.
Market Segmentation
By Product
Based on product, the market is segmented into diagnostic devices, diagnostic test kits, and standalone consumables & reagents.
The diagnostic devices segment accounted for the largest market share in 2025. These devices form an important part of hospital and laboratory infrastructure and support high-throughput women's health testing. Automation, faster turnaround times, and connectivity are encouraging upgrades to diagnostic equipment.
Meanwhile, the diagnostic test kits segment is projected to grow at a CAGR of 7.1% during the forecast period.
By Technology
By technology, the market is divided into immunoassay, molecular diagnostics, imaging, and others.
Immunoassay held the largest market share in 2025 because of its cost-effectiveness and scalability in routine women's health testing. Applications include fertility and reproductive hormone testing, pregnancy-related markers, and oncology-related testing. The segment is expected to account for 32.6% of the market in 2026.
The molecular diagnostics segment is projected to grow at a CAGR of 6.7% during the forecast period.
By Application
The market is segmented into cancer, infectious diseases, osteoporosis, pregnancy, fertility & prenatal diagnostics, and others.
The cancer segment held the largest share in 2025 and is projected to account for 37.5% of the market in 2026. Rising demand for breast and cervical cancer screening, imaging, biopsy, and pathology is supporting the segment.
The infectious diseases segment is expected to expand at a CAGR of 6.8% during the forecast period.
By End-user
Based on end-user, the market is categorized into hospitals, specialty clinics, diagnostic laboratories, homecare, and others.
Hospitals dominated the market in 2025 because they conduct substantial volumes of pregnancy tests, cancer screenings, infectious disease tests, and other women's health diagnostics. The segment is expected to hold a 36.1% share in 2026.
The diagnostic laboratories segment is projected to grow at a CAGR of 7.0% during the forecast period.
Key Players
Prominent companies operating in the women health diagnostics market include Hologic, Inc., GE HealthCare, Koninklijke Philips N.V., Thermo Fisher Scientific Inc., Hoffmann-La Roche Ltd, Cardinal Health, Inc., Quest Diagnostics Incorporated, Abbott, BD, and Aspira Women's Health.
In 2025, Hologic, GE HealthCare, and Koninklijke Philips held major market positions. These companies are focusing on product launches, strategic collaborations, distribution expansion, and partnerships to strengthen their market presence.
Regional Analysis
North America
North America held the largest market share in 2025, generating USD 9.38 billion and accounting for 34.65% of global revenue. Increasing demand for osteoporosis testing and women's health diagnostics is supporting regional growth.
The U.S. women health diagnostics market is projected to reach USD 9.09 billion in 2026, representing approximately 31.6% of global revenue.
Asia Pacific
Asia Pacific is expected to reach USD 8.35 billion in 2026, making it the second-largest regional market. The region is benefiting from a large patient population affected by breast cancer, osteoporosis, and infectious diseases.
China is expected to generate approximately USD 3.39 billion, while India is projected to reach USD 1.90 billion in 2026. Japan is expected to generate approximately USD 1.25 billion.
Europe
Europe is projected to reach USD 5.90 billion in 2026 and register a CAGR of 5.8% during the forecast period. The strong presence of specialty clinics and diagnostic laboratories is supporting regional expansion. Germany and the U.K. are expected to reach approximately USD 1.58 billion and USD 0.96 billion, respectively, in 2026.
Latin America and Middle East & Africa
Latin America is projected to reach approximately USD 2.96 billion in 2026, supported by increasing government initiatives for women's health diagnosis. The GCC market is expected to reach approximately USD 0.92 billion during the same year.
Competitive Landscape
Competition in the women health diagnostics market is focused on new product launches, partnerships, technology integration, and geographic expansion. Leading companies are strengthening their portfolios through advanced imaging, molecular diagnostics, test kits, and at-home testing solutions.
Recent developments include BD's FDA application for an at-home HPV self-collection test in July 2025 and Abbott's FDA clearance in May 2025 for its Alinity m STI Assay, which can simultaneously detect and differentiate four common STIs from a single swab or urine sample.
Future Outlook
The future of the women health diagnostics market is expected to be shaped by AI-enabled imaging, decentralized diagnostics, self-collection, at-home testing, and growing participation in screening programs.
The shift toward decentralized and at-home diagnostic pathways presents significant opportunities. In May 2025, the U.S. FDA approved the first at-home cervical cancer screening test from Teal Health, creating additional possibilities for direct-to-consumer and telehealth-based screening.
However, operational complexity, reimbursement gaps, patient follow-up, sample logistics, and regulatory requirements will remain important challenges. AI implementation also requires validation across populations, integration with existing healthcare systems, clinician trust, and ongoing performance monitoring.
Get a free sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/women-s-health-diagnostics-market-111885
Conclusion
The global women health diagnostics market is expected to maintain steady growth through 2034 as screening programs expand and awareness of women's health conditions increases. The market is projected to rise from USD 28.77 billion in 2026 to USD 47.66 billion by 2034, registering a CAGR of 6.5%.
Diagnostic devices, immunoassays, cancer diagnostics, and hospital-based testing remain important market segments, while AI-enabled imaging, molecular diagnostics, self-collection, and at-home testing are creating new growth opportunities.
Frequently Asked Questions
How big is the global women health diagnostics market?
According to Fortune Business Insights, the global women health diagnostics market was valued at USD 27.07 billion in 2025 and is projected to reach USD 47.66 billion by 2034.What is the CAGR of the women health diagnostics market?
The women health diagnostics market is projected to grow at a CAGR of 6.5% from 2026 to 2034.Which product segment dominates the women health diagnostics market?
The diagnostic devices segment dominated the market by product in 2025, supported by their essential role in hospitals and laboratories and ongoing upgrades involving automation, connectivity, and faster turnaround times.Which region dominated the women health diagnostics market in 2025?
North America dominated the market in 2025, accounting for 34.65% of global revenue and generating USD 9.38 billion.What are the major trends in the women health diagnostics market?
Key trends include AI-enabled women's imaging and workflow automation, decentralized diagnostics, self-collection, and at-home testing. These developments are supporting more accessible and efficient approaches to women's health screening and diagnosis.
Uncover Japan’s Market Trends Explore the Latest Women Health Diagnostics Market Insights
Top comments (0)